

Bill No. CS for CS for SB 370

Amendment No. Barcode 761516

1 forms provided by the department. This section does not apply
2 to:

3 (a) Pharmacists employed by pharmacies that
4 participate in the program provided by Rule 64B16-27.300,
5 Florida Administrative Code or health care practitioners
6 working in facilities that administer medications dispensed
7 from those pharmacies; or

8 (b) Pharmacists employed by pharmacies that have
9 notified the Board of Pharmacy that they will establish a
10 continuous quality-improvement program consistent with the
11 requirements of Rule 64B16-27.300, Florida Administrative
12 Code.

13 (4) The required notification to the department must
14 be submitted in writing by certified mail and postmarked
15 within 15 days after the pharmacist or health care
16 practitioner became aware of the patient's allegation that a
17 pharmaceutical adverse incident has occurred.

18 (5) Effective July 1, 2004, subject to subsequent act
19 of the Legislature and a specific appropriation sufficient to
20 cover the actual costs, the department shall review each
21 incident and determine whether it potentially involved conduct
22 by a pharmacist or health care practitioner who is subject to
23 disciplinary action, in which case section 465.073, Florida
24 Statutes, applies. Disciplinary action, if any, shall be
25 taken by the board under which the pharmacist or health care
26 practitioner is licensed.

27 (6) The Department of Health shall adopt forms and
28 rules for administering this section.

29 Section 43. Section 42 of this act shall take effect
30 only upon the effective date of legislation that makes any
31 such information provided to the Department of Health

Bill No. CS for CS for SB 370

Amendment No. ____ Barcode 761516

1 confidential and exempt from section 119.07(1), Florida
2 Statutes, and Section 24(a) of Article I of the State
3 Constitution, until 10 days after probable cause is found that
4 a violation of law occurred. Such legislation must also
5 provide that information may be used by the department or the
6 Board of Pharmacy only in a disciplinary proceeding brought
7 against the pharmacist or by the department in any study of
8 adverse incidents without identifying the patient, pharmacist,
9 pharmacy, office, or entity by name, location, or other
10 identifier.

11
12 (Redesignate subsequent sections.)

13
14
15 ===== T I T L E A M E N D M E N T =====

16 And the title is amended as follows:

17 On page 4, line 5, after the semicolon

18

19 insert:

20 creating the "Ernest Belles Act"; defining the
21 term "pharmaceutical adverse incident" and
22 requiring that such incidents be reported to
23 the Department of Health; providing exceptions;
24 requiring the department to review reported
25 incidents to determine whether the incidents
26 potentially involve conduct by a health care
27 practitioner that is subject to disciplinary
28 action; specifying that any disciplinary action
29 shall be taken by the appropriate board;
30 providing for the adoption of rules and forms;

31